It is not consistent to stop screening women after age 50 because the risk of cervical cancer - even after several negative smear results - is similar to that at younger ages, concludes a study published on bmj.com today.
When it comes to cervical cancer, many St. Louis women are not accessing the tools available to protect themselves from this preventable disease, according to recent survey findings released by the National Women's Health Resource Center (NWHRC), a non-profit organization dedicated to providing health education to women. The survey shows that while many St. Louis women are aware of important prevention tools like the HPV vaccine, the Pap test and the HPV test, they are missing the annual physician visits where they could receive these technologies.
The Department of Health has joined forces with the Immunisation Alliance of Western Australia and a cervical cancer survivor to urge young women to take up the free cervical cancer vaccine.
Michelle Arrowsmith was just 31-years-old when she was diagnosed with cervical cancer in 2006 and underwent urgent life-saving surgery.
Jade Goody, the British reality TV star, has died of cervical cancer at age 27. It is reported that she died quietly in her sleep Sunday, March 22, 2009. She had lived the past 7 years of her life in front of the camera. She leaves behind her new husband, Jack Tweed, and her two sons, Freddie and Bobby Jack.
Jade Goody became a face for cervical cancer. Her story inspired many to have Pap smears. It is being called the “Jade Goody effect.”
A panel of experts is to carry out an evidence review to determine whether women under the age of 25 should be routinely screened for cervical cancer, Health Minister Ann Keen announced today.
Cervical screening currently starts at age 25 years in England, in line with World Health Organisation recommendations and the advice of leading experts in this country including the independent Advisory Committee on Cervical Screening (ACCS).
All girls and young women in Wales born between 1 September 1991 and 31 August 1995 will be offered the human papillomavirus (HPV) vaccine during school year 2009-10, announced Health Minister Edwina Hart.
The Welsh Assembly Government is investing about £9 million to accelerate the planned two-year catch-up campaign to ensure that an additional 40,000 girls and young women are offered protection against cervical cancer.
This follows the success of the inaugural routine programme which began last Autumn for some 20,000 girls aged 12 – 13 years old.
The U.S. Food and Drug Administration yesterday approved the first DNA test that identifies the two types of human papillomavirus (HPV) that cause the majority of cervical cancers among women in the United States.
The test, called Cervista HPV 16/18, detects the DNA sequences for HPV type 16 and HPV type 18 in cervical cells. Differentiating these HPV types gives health care professionals more information on a patient’s risk of subsequently developing cervical cancer.
New research shows for the first time that certain types of human papillomavirus (HPV), which cause cervical and some other types of cancer, can inhibit the production of a tiny single-stranded RNA called microRNA 34a, or miR-34a. Because previous research had demonstrated that microRNAs regulate important functions of the cell, the new finding provides insight into the mechanisms by which HPV contributes to the development of cancer and may lead to the development of treatments to counter HPV infection. Currently, such treatments do not exist.
Jade Goody, the British reality TV star, is dying of cervical cancer at age 27. For the past 7 years she had lived in front of the camera. Now she will approach her death the same way – in front of the camera as part of her ongoing reality show.
The HPV vaccine does not increase the risk of developing Guillain-Barre syndrome, according to a study released by the American Academy of Neurology. Guillain-Barre is a disorder that causes muscle weakness and tingling that can progress to paralysis.
Although it can be life-threatening, most people recover with few remaining problems. The disorder often occurs after an infection; the body’s immune system attacks the peripheral nervous system.
Less than two years after the HPV vaccine was approved as a routine vaccination for girls aged 11 and older, one-quarter of California adolescent girls have started the series of shots that protect against human papillomavirus, which is strongly linked to cervical cancer.
Additionally, a majority of teen girls, parents and young women in California say they would like to have the vaccine, according to a new policy brief released by the UCLA Center for Health Policy Research.
Nearly 400 women in North Carolina were diagnosed with cervical cancer last year, and 124 died from the disease. African American and Hispanic women have a greater risk of developing cervical cancer than white women, and the death rate is 50 percent higher among both African American and Hispanic women.
January is Cervical Health Awareness month, and the focus is on raising awareness of the importance of prevention and screening for cervical cancer.
The Florida Department of Health (DOH) recognizes January as Cervical Health Awareness Month, a time to educate, encourage and empower women to visit their health care provider for information and screening for cervical cancer.
“Because approximately half of all cervical cancers occur in women who have never been screened, screening is particularly important in these women or women who have rarely been screened,” said Susan Fleming, DOH Cancer Program Administrator. “By taking action, you can reduce your cancer risk.”
The U.S. Food and Drug Administration has asked drug maker Merck & Co. for more information before it decides whether to expand approval for Gardasil, a human papillomavirus vaccine, Merck said Friday.
Gardasil is currently approved for females ages 9 to 26. Merck has asked the FDA to widen approval for its use in women aged 27 to 45, the Associated Press reported. The drug is designed to guard against HPV, which is responsible for most cases of cervical cancer.
State officials are marking Cervical Cancer Awareness Month today by encouraging women to receive a "Pap" screening test because early screening can help improve cervical cancer survival. A "Pap" exam can detect cervical abnormalities at an early, treatable stage before they develop into cancer. Also, women between the ages of 11 and 26 may want to discuss the human papillomavirus (HPV) vaccine with their health care provider since the vaccine helps prevent the disease which causes most cervical cancer.
As a part of National Cervical Health Awareness Month, Acting Secretary of Health Everette James today reminded women of the importance of cervical cancer prevention and the need for Pap tests.
“Every January as we begin a new year, we want to remind all Pennsylvanians to do what they can to improve their overall health,” said James. “This month, as we observe National Cervical Cancer Month, I want to remind our mothers, sisters, daughters and friends that yearly examinations are the best way to prevent cervical cancer.
More women in Kentucky should join the fight to end cervical cancer by getting vaccinated and undergoing regular screenings for the disease, the Kentucky Department for Public Health (DPH) announced today.
More than 70 per cent of 12-13 year old girls have already had their first HPV (human papillomavirus) jab since the vaccination campaign started in September, Public Health Minister Dawn Primarolo announced today. This figure will rise as more results come in.
The success of the campaign has prompted the Department of Health to announce that the catch up campaign to vaccinate girls aged 13-17 years will be brought forward to next year.
Early figures out today show that:
* 148 of the 152 Trusts have already started vaccinating young girls;
The public's concerns about costs and increased promiscuity among teenagers appear to be hindering use of a cervical cancer vaccine against the human papilloma virus (HPV) to prevent life-threatening diseases, according to a study by researchers at Yale School of Public Health.
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the BD FocalPoint GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.
Women living in the most deprived areas of England are nearly twice as likely to be diagnosed with cervical cancer than their affluent counterparts – according to a report presented by national cancer director Professor Mike Richards at the Britain Against Cancer conference.
The report, published by the National Cancer Intelligence Network (NCIN), reveals a 'deprivation gap' that researchers believe is mainly fuelled by a lower uptake of cervical screening in deprived areas.
Black women who have advanced and recurrent cervical cancer seem to have fewer side effects from a commonly used form of chemotherapy than white women, according to a study published in the November issue of the American Journal of Obstetrics and Gynecology, Reuters Health reports. Cisplatin, a platinum-based version of chemotherapy, is a common treatment for various types of cancer.
As testing for high-risk types of the human papillomavirus (HPV) emerges as the gold standard in cervical cancer prevention, scientists are already researching how to determine even more precisely who is most likely to develop the disease and thus are in need of more immediate intervention.
Merck & Co has presented data on Gardasil which shows that the vaccine, which is approved for cervical cancer, is also effective in the prevention of human papillomavirus-related disease in young men.
Data from a Phase III trial in men aged 16 to 26,which was presented at the European Research Organisation on Genital Infection and Neoplasia meeting in Nice, France, showed that Gardasil prevented 90% of external genital lesions caused by human papillomavirus types 6, 11, 16 and 18. These are the only data evaluating efficacy of any HPV vaccine in preventing disease in males, Merck noted.
All girls who were born between 1 September 1990 and 31 August 1991 will be offered the human papillomavirus (HPV) vaccine to protect them against the viruses that are the most common cause of cervical cancer, Health Minister Edwina Hart has announced today.
This is in addition to the routine vaccination programme that has been introduced for all 12 and 13 year old girls this year and the catch-up campaign planned for the next two years.
Using high-resolution magnetic resonance imaging (MRI) with a special vaginal coil, a technique to measure the movement of water within tissue, researchers may be able to identify cervical cancer in its early stages, according to a new study being published in the November issue of Radiology.
The new technique offers better imaging of smaller tumors and may also improve surgical options when fertility-sparing procedures are being considered.
One in four teenage girls has begun the process of vaccination against human papillomavirus (HPV) with the three-shot series of Gardasil, according to the 2007 National Immunization Survey-Teen. In March 2007 the Advisory Committee on Immunization Practices (ACIP) recommended that all girls age 11 or 12 be routinely vaccinated with three doses of quadrivalent HPV vaccine. The new survey was the first official government report on compliance.
Some immigrant and women's rights advocacy groups are raising concern about a new U.S. Citizenship and Immigration Services rule that adds the human papillomavirus vaccine to the list of required vaccinations for female immigrants seeking U.S. citizenship, the Dallas Morning News reports.
A new HPV test showed to be accurate, fast and cheap and will be soon widely acceptable in rural areas. This will help women in developing countries to earlier diagnose viruses causing cervical cancer.
Cervical cancer is the number two cancer in women, with 500000 newly diagnosed cases and 300000 deaths each year. In most cases (more than 85%) it occurs in developing world. Human Papilloma Virus (HPV) is a type of infection occurring on cervix and later causing genital warts, cervical and other cancers. The sooner HPV is diagnosed, the lower cervical cancer risk is.
QIAGEN's careHPV test provides 'substantially more accurate' front-line screening.
A new HPV test developed by QIAGEN specifically for use in regions of the world with scarce resources is "substantially" more accurate in identifying women with cervical disease than the current methods (Pap testing and visual inspection) in these countries. The first published study of patient outcomes with QIAGEN's careHPV test – developed with support from PATH, a non-profit global health organization – appears in the October issue of Lancet Oncology.